America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does AOH1996’s mechanism of action differ from other cancer-targeting drugs currently in development?
**Interview with Dr. Linda Malkas, Lead Researcher at City of Hope Hospital**
**Editor:** Dr. Malkas, thank you for joining us today. Can you tell us more about this groundbreaking drug, AOH1996, and how it specifically targets cancer cells?
**Dr. Malkas:** Thank you for having me. AOH1996 is an innovative cell-killing drug that leverages a unique approach to chemotherapy. We designed this molecule to specifically target the cancer variant of a protein called PCNA, which plays a crucial role in DNA replication and tumor growth. Think of PCNA as a major airline terminal; our drug acts like a blizzard disrupting operations, effectively shutting down the flow of cancer cells.
**Editor:** That’s a fascinating analogy! What types of cancers have shown promising results with AOH1996 during your research?
**Dr. Malkas:** Our clinical studies indicate that AOH1996 has been effective against various types of solid tumors, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. This broad spectrum of effectiveness is particularly encouraging for future treatment possibilities.
**Editor:** In your recent publication in ‘Cell Chemical Biology’, you mentioned testing AOH1996 on over 70 cancer cell lines. What did those results indicate about the drug’s efficacy?
**Dr. Malkas:** The results were very promising! AOH1996 selectively killed cancer cells by disrupting their normal reproductive cycle, thus halting their proliferation. This selective targeting is crucial as it minimizes damage to healthy cells, which is a significant concern with traditional chemotherapy approaches.
**Editor:** What are the next steps in the development of AOH1996?
**Dr. Malkas:** The next phase involves advancing our findings through clinical trials in humans. We are eager to explore how AOH1996 performs in a clinical setting and continue our mission of providing effective cancer treatments that improve patient outcomes.
**Editor:** Thank you, Dr. Malkas, for sharing your insights. This research represents a significant step forward in cancer treatment, and we look forward to hearing more about its advancements in the future.
**Dr. Malkas:** Thank you! It’s an exciting time for cancer research, and we’re hopeful about the impact AOH1996 could have on patients worldwide.